AU 101

Drug Profile

AU 101

Alternative Names: AU101

Latest Information Update: 13 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aurora BioPharma
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma; Osteosarcoma
  • Preclinical Breast cancer

Most Recent Events

  • 12 Jul 2016 Phase-I/II clinical trials in Glioblastoma (Second-line therapy or greater) (Parenteral) before July 2016
  • 12 Jul 2016 Phase-I/II clinical trials in Osteosarcoma (IV) before July 2016
  • 12 Jul 2016 Preclinical trials in Breast cancer in USA (Parenteral) before July 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top